Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer to Undertake Development of Injectable Metronidazole
September 20, 2010
- JMHA to Jointly Purchase Drugs
September 20, 2010
- Takara Bio Licenses Nucleic Acid Refining Reagent from Macherey-Nagel
September 20, 2010
- Eisai Launches Glufast in China
September 20, 2010
- Rivaroxaban Non-Inferior to Standard Therapy: Bayer
September 20, 2010
- Sawai Prepares for Biosimilars Business
September 20, 2010
- Apixaban More Effective than Aspirin in AF: BMS/Pfizer
September 20, 2010
- Sandoz to Expand Range of Target Doctors for Somatropin Biosimilars
September 20, 2010
- JSNM to Promote Use of PET Drugs for Drug Discovery
September 20, 2010
- JGA to Stress That Equivalence Data Are Unnecessary for Generic IV Injectables
September 20, 2010
- Taxotere to Change Its Name to Prevent Mix-Ups with Taxol
September 20, 2010
- Pharmacists to No Longer Be Held Responsible for ADRs Due to Generic Substitution: JPA Vice President
September 20, 2010
- Korosho to Undertake Surveillance on Multi-Drug-Resistant Bacteria
September 20, 2010
- 12 APIs Included in NHI Price List
September 20, 2010
- TUS Research Team Develops Technology to Make Impurity-Free NSAIDs
September 20, 2010
- Chuikyo to Reconsider 14-Day Limit on Prescription of New Combination Drugs
September 20, 2010
- Telmisartan + Amlodipine More Effective than Either Drug Alone
September 20, 2010
- Nippon Chemiphar to Terminate Alliance with Nihon Chouzai
September 13, 2010
- Takeda Licenses Contrave from Orexigen
September 13, 2010
- 2010 ESC Congress Held in Stockholm
September 13, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…